Want to see TLPH full AI Analyst Report?
TLPH Stock Chart & Stats
$1.35
-$0.02(-1.46%)
At close: 4:00 PM EDT
$1.35
-$0.02(-1.46%)
Day’s Range― - ―
52-Week Range$0.50 - $1.57
Previous CloseN/A
Volume89.66K
Average Volume (3M)2.97M
Market Cap
$61.77M
Enterprise Value$67.22
Total Cash (Recent Filing)$17.08M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 16, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding51,905,796
10 Day Avg. Volume675,544
30 Day Avg. Volume2,969,035
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)2.84
Price to Sales (P/S)1726.72
P/FCF Ratio-4.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.07
Enterprise Value/Gross Profit0.07
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside122.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressAdvanced enrollment and activated sites reduce development uncertainty and move Talphera toward a registrational readout. Successful completion could support a PMA filing and create a pathway to commercial revenue from NEPHRO CRRT.
Clinical Validation And Adoption PotentialGuideline recognition and established overseas use provide external validation for nafamostat. These factors may support physician confidence, payer discussions and adoption if U.S. regulatory approval is achieved.
Favorable Treatment Profile And Market ExpansionPredictable dosing and rapid therapeutic control could improve clinical usability in hospitals. The larger procedure estimate expands the potential addressable market, strengthening the commercial opportunity for a successful product launch.
Bears Say
Persistent Cash BurnOngoing operating and free-cash-flow deficits show that Talphera cannot currently fund development from operations. Continued spending before commercialization increases dependence on financing and could dilute shareholders or constrain execution.
Minimal Revenue And Substantial LossesThe company lacks a meaningful revenue base to offset research, regulatory and corporate costs. Large recurring losses will likely persist until commercialization, leaving results highly dependent on clinical success and future product revenue.
Financing And Regulatory Execution RiskThe planned runway depends on financing tranches that require conditions to be met, while the regulatory timetable depends on enrollment, data readout and FDA interactions. Delays or unmet conditions could force additional capital raising.
Talphera News
TLPH FAQ
What was Talphera’s price range in the past 12 months?
Talphera lowest stock price was $0.50 and its highest was $1.57 in the past 12 months.
What is Talphera’s market cap?
Talphera’s market cap is $61.77M.
When is Talphera’s upcoming earnings report date?
Talphera’s upcoming earnings report date is Nov 16, 2026 which is in 82 days.
How were Talphera’s earnings last quarter?
Talphera released its earnings results on Aug 12, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.062 by $0.002.
Is Talphera overvalued?
According to Wall Street analysts Talphera’s price is currently Undervalued.
Does Talphera pay dividends?
Talphera does not currently pay dividends.
What is Talphera’s EPS estimate?
Talphera’s EPS estimate is -0.05.
How many shares outstanding does Talphera have?
Talphera has 51,905,796 shares outstanding.
What happened to Talphera’s price movement after its last earnings report?
Talphera reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.062. Following the earnings report the stock price went down -13.571%.
Which hedge fund is a major shareholder of Talphera?
Currently, no hedge funds are holding shares in TLPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Talphera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (122.22% Upside)
$3.00 (122.22% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
62.31%
Trailing 12-Months
Company Description
Talphera
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
TLPH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents strong clinical and commercial momentum: 75% enrollment in a registrational trial, positive DSMB feedback, KDIGO recognition of nafamostat, expanded market sizing (+21%), and encouraging dosing/titration data. Financially the company has runway assumptions but relies on conditional financing (~$16M) and faces modest near-term expense increases and regulatory timing uncertainty. On balance the achievements and favorable clinical/commercial signals outweigh the financing and timing risks.View all TLPH earnings summariesTLPH Stock 12 Month Forecast
Average Price Target
$3.00
▲(122.22% Upside)
Technical Analysis
Sonoma Pharmaceuticals
―
Perrigo Company
―
Organogenesis Holdings
―
Evolus
―
Journey Medical Corp
―
Ownership Overview
6.01% Insiders
1.48% Mutual Funds
40.78% Other Institutional Investors
50.38% Public Companies and
Individual Investors